Home › Bronchial Cancer
Bronchial Cancer clinical trials recruiting in the U.S.
8 studies for Bronchial Cancer are recruiting participants at sites across the United States.
Cities with the most studies
- New York City, NY6 studies
- Houston, TX5 studies
- Boston, MA4 studies
- Columbus, OH4 studies
- Pittsburgh, PA4 studies
- Chicago, IL3 studies
- Memphis, TN3 studies
- Los Angeles, CA3 studies
- Miami, FL3 studies
- Cincinnati, OH3 studies
- Tampa, FL3 studies
- Durham, NC3 studies
- Minneapolis, MN3 studies
- Indianapolis, IN3 studies
- Arlington, VA3 studies
By state
- California6 studies
- Colorado3 studies
- Florida6 studies
- Illinois5 studies
- Indiana3 studies
- Kentucky3 studies
- Massachusetts4 studies
- Michigan5 studies
- Minnesota3 studies
- New York6 studies
- North Carolina3 studies
- Ohio6 studies
- Pennsylvania5 studies
- Tennessee4 studies
- Texas5 studies
- Virginia4 studies
- Washington3 studies
Recently updated studies
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06128551A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT06119581Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 1, 2026 · NCT07185997Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
RecruitingPhase 2
Ages 18 to 70 · All sexes · Updated Jun 26, 2026 · NCT04614103A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
RecruitingPhase 1/2
Ages 18 to 70 · All sexes · Updated Jun 11, 2026 · NCT05361174A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated May 27, 2026 · NCT03093116Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 21, 2026 · NCT06623656Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
Recruiting
Ages 18 and older · All sexes · Updated Feb 19, 2026 · NCT02984761From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.